Long‐term effectiveness of eculizumab: Data from the International PNH Registry
European Journal of Haematology · 2023-11 · 111 (5) · 796-804
DOI: 10.1111/ejh.14080 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 15.09.2023. Verfasst von Louis Terriou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Autoimmunes Systémiques…. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.
Abstract (Originalsprache)
Objectives
Data from the International PNH Registry (NCT01374360) were used to estimate the overall survival and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab‐treated patients with paroxysmal nocturnal hemoglobinuria (PNH) compared with a contemporaneous untreated cohort.
Methods
Patients enrolled in the Registry from March 16, 2007, to February 14, 2022, were included. Treated patients received eculizumab for >35 days; untreated patients did not receive eculizumab at any time. Univariable and multivariable analyses were performed using a Cox proportional hazards regression model comparing eculizumab treatment periods to untreated periods and were adjusted for baseline covariates (e.g., high disease activity [HDA], transfusion dependency, and eculizumab treatment status).
Results
The analysis included 4118 patients. The univariable hazard ratio (HR) (95% CI) for mortality in eculizumab‐treated time versus untreated time was 0.51 (0.41–0.64; p < 0.0001). Significant baseline covariates included age, sex, history of bone marrow failure, ≥4 erythrocyte transfusions within 12 months before baseline, and an estimated glomerular filtration rate ≤ 60 mL/min/1.73 m 2 (all p < 0.0001). In the adjusted analysis, patients with baseline HDA had the greatest reduction in mortality risk (HR [95% CI], 0.51 [0.36–0.72]). Treated patients had approximately 60% reduction in TE/MAVE risk during treated versus untreated time (HR [95% CI]: TE: 0.40 [0.26–0.62], MAVE: 0.37 [0.26–0.54]; p < 0.0001).
Conclusion
Using data from the largest Registry of patients with PNH, with ≥14 years of overall follow‐up, we demonstrate that treatment with eculizumab conferred a 49% relative benefit in survival and an approximately 60% reduction in TE/MAVE risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Institut de Recherch…
- Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Central Coast Haematology, North Gosford, New South Wales, Australia.
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen and University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Jeff Szer, Christopher J Patriquin
Förderung
- Alexion, AstraZeneca Rare Disease
- Alexion Pharmaceuticals
Zitieren
APA
Terriou, L., Lee, J. W., Forsyth, C., Griffin, M., Szer, J., Röth, A., Gustovic, P., Metzger, J., Patel, A. S., & Patriquin, C. J. (2023). Long‐term effectiveness of eculizumab: Data from the International PNH Registry. European Journal of Haematology, 111(5), 796-804. https://doi.org/10.1111/ejh.14080
Vancouver
Terriou L, Lee JW, Forsyth C, Griffin M, Szer J, Röth A, et al. Long‐term effectiveness of eculizumab: Data from the International PNH Registry. European Journal of Haematology. 2023;111(5):796-804. doi:10.1111/ejh.14080
BibTeX
@article{Terriou2023,
author = {Terriou, Louis and Lee, Jong Wook and Forsyth, Cecily and Griffin, Morag and Szer, Jeff and Röth, Alexander and Gustovic, Philippe and Metzger, Jesse and Patel, Ami S and Patriquin, Christopher J},
title = {Long‐term effectiveness of eculizumab: Data from the International PNH Registry},
journal = {European Journal of Haematology},
year = {2023},
volume = {111},
number = {5},
pages = {796--804},
doi = {10.1111/ejh.14080}
}
EUVIMED